Table 3 Psychological variables for participants assessed at each time-point
| Â | N | Baseline | 12 weeks | 24 weeks | P value b |
|---|---|---|---|---|---|
State anxiety | Â | Â | Â | Â | 0.359 |
Treatment | 3 | 35.7 (14.0) | 42.7 (10.0) | 52.3 (24.4) | |
Surveillance | 5 | 38.8 (15.1) | 40.6 (18.0) | 43.2 (18.3) | |
Trait anxiety | Â | Â | Â | Â | 0.080 |
Treatment | 3 | 37.3 (9.6) | 42.7 (8.1) | 32.7 (11.0) | |
Surveillance | 5 | 34.4 (15.0) | 36.4 (20.8) | 34.8 (16.1) | |
FACT-G | Â | Â | Â | Â | 0.605 |
Treatment | 3 | 75.7 (12.7) | 67.3 (9.7) | 73.3 (18.6) | |
Surveillance | 10 | 81.9 (19.0) | 83.2 (16.3) | 83.2 (17.7) | |
FACT-ES | Â | Â | Â | Â | 0.346 |
Treatment | 3 | 104.0 (43.8) | 119.0(16.5) | 124.6 (17.1) | |
Surveillance | 10 | 138.3(26.4) | 138.3 (26.5) | 140.9 (25.2) | |
FACT-O | Â | Â | Â | Â | 0.625 |
Treatment | 3 | 105.3 (20.5) | 94.9 (10.16) | 103.9 (22.7) | |
Surveillance | 10 | 116.3 (22.8) | 117.8 (22.4) | 117.3 (22.8) | |
FACT-F | Â | Â | Â | Â | 0.693 |
Treatment | 3 | 103.3 (23.7) | 96.9 (11.4) | 105.3(27.8) | |
Surveillance | 10 | 123.4 (28.9) | 124.2 (26.9) | 124.5 (27.3) | |
FACT-GOG | Â | Â | Â | Â | 0.401 |
Treatment | 3 | 108.3 (21.1) | 99.9 (6.4) | 105.6 (27.1) | |
Surveillance | 10 | 119.5 (21.6) | 117.0 (22.4) | 119.2 (23.0) | |
CBI | Â | Â | Â | Â | 0.742 |
Treatment | 3 | 95.7 (11.0) | 101.7 (9.9) | 101.7 (9.6) | |
Surveillance | 3 | 94.7 (16.0) | 100.0 (10.6) | 89.0 (14.0) | |
CESD | Â | Â | Â | Â | 0.797 |
Treatment | 3 | 16.3 (12.5) | 17 (7.2) | 13.3 (15.3) | |
Surveillance | 5 | 10.2 (8.0) | 6 (6.6) | 9.0 (9.6) | |
PCL | Â | Â | Â | Â | 0.270 |
Treatment | 3 | 32.7 (8.1) | 37.7 (9.0) | 29.0 (10.6) | |
Surveillance | 8 | 33.5 (10.2) | 33.0 (11.0) | 31.3 (11.8) | |
POMS | Â | Â | Â | Â | 0.983 |
Treatment | 3 | 26 (3.5) | 34.0 (14.0) | 30.7 (7.5) | |
Surveillance | 10 | 41.4 (15.8) | 35.1 (27.0) | 39.4 (19.7) |